GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » ROE % Adjusted to Book Value

Instituto Rosenbusch (BUE:ROSE) ROE % Adjusted to Book Value : -12.10% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch ROE % Adjusted to Book Value?

Instituto Rosenbusch's ROE % for the quarter that ended in Sep. 2024 was -15.61%. Instituto Rosenbusch's PB Ratio for the quarter that ended in Sep. 2024 was 1.29. Instituto Rosenbusch's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -12.10%.


Instituto Rosenbusch ROE % Adjusted to Book Value Historical Data

The historical data trend for Instituto Rosenbusch's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch ROE % Adjusted to Book Value Chart

Instituto Rosenbusch Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.32 -6.70 -7.71 -6.98 26.04

Instituto Rosenbusch Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 275.73 22.94 32.26 -33.06 -12.10

Competitive Comparison of Instituto Rosenbusch's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's ROE % Adjusted to Book Value falls into.


;
;

Instituto Rosenbusch ROE % Adjusted to Book Value Calculation

Instituto Rosenbusch's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=36.98% / 1.42
=26.04%

Instituto Rosenbusch's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-15.61% / 1.29
=-12.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instituto Rosenbusch ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Instituto Rosenbusch Business Description

Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.